Biocompatible gelatin nanoparticles for tumor-targeted delivery of polymerized siRNA in tumor-bearing mice

Authors
Lee, So JinYhee, Ji YoungKim, Sun HwaKwon, Ick ChanKim, Kwangmeyung
Issue Date
2013-11-28
Publisher
ELSEVIER SCIENCE BV
Citation
JOURNAL OF CONTROLLED RELEASE, v.172, no.1, pp.358 - 366
Abstract
Structural modifications of the siRNA backbone improved its physiochemical properties for incorporating in gene carriers without loss of gene-silencing efficacy. These modifications provide a wider variety of choice of vector systems for siRNA delivery. We developed a tumor-targeted siRNA delivery system using polymerized siRNA (poly-siRNA) and natural polymer gelatin. The polymerized siRNA (poly-siRNA) was prepared through self-polymerization of thiol groups at the 5'-end of sense and anti-sense strands of siRNA and was encapsulated in the self-assembled thiolated gelatin (tGel) nanoparticles (NPs) with chemical cross-linking. The resulting poly-siRNA-tGel (psi-tGel) nanoparticles (average of 145 nm in diameter) protect siRNA molecules from enzymatic degradation, and can be reversibly reduced to release functional siRNA molecules in reductive conditions. The psi-tGel NPs presented efficient siRNA delivery in red fluorescence protein expressing melanoma cells (RFP/B16F10) to down-regulate target gene expression. In addition, the NPs showed low toxicity at a high transfection dose of 125 mu g/ml psi-tGel NPs, which included 1 mu M of siRNA molecules. In tumor-bearing mice, the psi-tGel NPs showed 2.8 times higher tumor accumulation than the naked poly-siRNA, suggesting tumor-targeted siRNA delivery of psi-tGel NPs. Importantly, the psi-tGel NPs induced effective tumor RFP gene silencing in vivo without remarkable toxicity. The psi-tGel NPs have great potential for a systemic siRNA delivery system for cancer therapy, based on their characteristics of low toxicity, tumor accumulation, and effective siRNA delivery. (C) 2013 Elsevier B. V. All rights reserved.
Keywords
DRUG-DELIVERY; GENE DELIVERY; CATIONIC LIPIDS; GLUTATHIONE; TOXICITY; THERAPEUTICS; STABILITY; COMPLEXES; EFFICACY; THERAPY; DRUG-DELIVERY; GENE DELIVERY; CATIONIC LIPIDS; GLUTATHIONE; TOXICITY; THERAPEUTICS; STABILITY; COMPLEXES; EFFICACY; THERAPY; Gelatin; Nanoparticles; Polymerized siRNA; siRNA delivery system; Tumor-targeted delivery
ISSN
0168-3659
URI
https://pubs.kist.re.kr/handle/201004/127423
DOI
10.1016/j.jconrel.2013.09.002
Appears in Collections:
KIST Article > 2013
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE